Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Change in Account Payables: 2019-2025

Historic Change in Account Payables for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $2.1 million.

  • Eton Pharmaceuticals' Change in Account Payables rose 284.42% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 1129.97%. This contributed to the annual value of $2.3 million for FY2024, which is 4273.58% up from last year.
  • As of Q3 2025, Eton Pharmaceuticals' Change in Account Payables stood at $2.1 million, which was down 70.79% from $7.3 million recorded in Q2 2025.
  • Eton Pharmaceuticals' 5-year Change in Account Payables high stood at $7.3 million for Q2 2025, and its period low was -$1.3 million during Q4 2021.
  • In the last 3 years, Eton Pharmaceuticals' Change in Account Payables had a median value of $552,000 in 2024 and averaged $1.1 million.
  • Per our database at Business Quant, Eton Pharmaceuticals' Change in Account Payables slumped by 1,033.09% in 2021 and then skyrocketed by 5,688.46% in 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Change in Account Payables (Quarterly) stood at -$1.3 million in 2021, then surged by 156.11% to $712,000 in 2022, then tumbled by 85.25% to $105,000 in 2023, then surged by 1,311.43% to $1.5 million in 2024, then soared by 284.42% to $2.1 million in 2025.
  • Its Change in Account Payables was $2.1 million in Q3 2025, compared to $7.3 million in Q2 2025 and $705,000 in Q1 2025.